AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Psyence Biomedical Ltd. Common Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01L71H3Y0
4.17▲ 0.04 (1.09%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
4.12
Day's Range
4.06 – 4.29
52-Week Range
0.61 – 16.96
Volume
13.2K
Avg Volume
72.5K
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2024-01-26
Share count as of March 31, 2026

Psyence Biomedical Ltd. Common Shares (PBM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Psyence Biomedical Ltd. Common Shares (PBM)
What is Psyence Biomedical Ltd. Common Shares's Market Cap?
Psyence Biomedical Ltd. Common Shares's Market Cap is $9.6M, based on as-reported figures from SEC (XBRL) filings.
What is Psyence Biomedical Ltd. Common Shares's Enterprise Value?
Psyence Biomedical Ltd. Common Shares's Enterprise Value is $2.4M, based on as-reported figures from SEC (XBRL) filings.
What is Psyence Biomedical Ltd. Common Shares's Net Income (TTM)?
Psyence Biomedical Ltd. Common Shares's Net Income (TTM) is -$6.9M, based on as-reported figures from SEC (XBRL) filings.
What is Psyence Biomedical Ltd. Common Shares's Diluted EPS (TTM)?
Psyence Biomedical Ltd. Common Shares's Diluted EPS (TTM) is -3.02, based on as-reported figures from SEC (XBRL) filings.
What is Psyence Biomedical Ltd. Common Shares's Net Debt?
Psyence Biomedical Ltd. Common Shares's Net Debt is -$7.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PBMAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Mar 31, 2025Mar 31, 2024Mar 31, 2023
Expenses
Sales and marketing
Research and development
General and administrative
Professional and consulting fees
Loss before other items
Other items
Other income
Other expense
Depreciation
Interest income
Interest expense
Foreign exchange loss
Listing expense—
Transaction expense—
Gain on debt settlement—
Fair value gain/(loss) on convertible note—
Fair value gain/(loss) on warrant liability
Fair value gain/(loss) on promissory notes—
Fair value loss on warrant exchange—
Fair value gain on investment in Psyence Labs Ltd
Fair value loss on digital assets
Share of losses from Associate
NET INCOME/(LOSS)